MedTrace Logo

Study to Investigate the Mechanism of Action of an Oral Enzyme Treatment With Bromelain, Trypsin and Rutoside Versus Placebo in Subjects With OsTeoarthritis

NCT05038410 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-11-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the pharmacodynamic profile of an oral enzyme treatment with Bromelain, Trypsin and Rutoside in subjects with osteoarthritis.

Conditions

Interventions

DRUG

Wobenzym®

Wobenzym®

OTHER

Placebo

Microcrystalline cellulose

Sponsors & Collaborators

  • Société des Produits Nestlé (SPN)

    collaborator INDUSTRY

  • Artialis

    collaborator INDUSTRY

  • Mucos Pharma GmbH & Co. KG

    lead INDUSTRY

Principal Investigators

  • Valerie Badot · Centre Hospitalier Universitaire (CHU) Brugmann

  • Didier Urbin-Choffray · Centre Hospitalier Regional de la Citadelle

  • Karl Brabants · Ziekenhuis Netwerk Antwerpen (ZNA) Middelheim

  • Jean-Emile Dubuc · Cliniques Universitaires Saint Luc UCL

  • Siddhartha Lieten · Universitair Ziekenhuis Brussel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-30
Primary Completion
2022-10-05
Completion
2022-10-05

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05038410 on ClinicalTrials.gov